The Role of St John's Wort (Hypericum Perforatum) and Orphanin Interaction in Depression Treatment

Yıl 2015, Cilt: 24 Sayı: 4, 531 - 541, 15.09.2015

Sena Yalçın Özge Boğa Ayper Pekmezekmek

https://doi.org/10.17827/aktd.44735

Cited By: 2

Öz

St. John’s Wort (Hypericum perforatum/ Cantarion) has been well-studied which has been showed to have antidepressant, antiviral, and antibacterial effects. St John's Wort gained popularity as an alternative treatment for mild to moderate depression. On the other hand, the neuropeptide, orphanin FQ/nociceptin (OFQ/N), is expressed in both neuronal and non-neuronal tissue. In the brain, OFQ/N has been investigated in relation to stress, anxiety, learning and memory, and addiction. The purpose opf this article is to review the current pharmacological, and clinical papers on St. John’s wort, to provide information on orphanin FQ/nociceptin and finally to evaluate probable interaction between two.

Anahtar Kelimeler

Antidepresant effect, Hypericum perforatum, orphanin FQ/nociceptin, St. John’s wort

Sarı Kantaron (Hypericum Perforatum) ile Orfanin Etkileşiminin Depresyon Tedavisindeki Rolü

Öz

Sarı Kantaron (Hypericum perforatum)bitkisi çok iyi çalışılmışbir bitkidir.Elde edilen veriler sonucu bu bitkinin farmakolojik olarak antidepresan, antiviral, and antibakteriyel olduğu ileri sürülmüştür. Araştırıcılar kantaronun özellikle antidepresan etkisi olan bir bitki olduğunu ileri sürmüşlerdir. Diğer yandan bir nöropeptidolan Orfanin(OFQ/Nosiseptin) immün sistemi de içine alan hem nöronal hem de nöronal olmayan dokuda bulunur. Beyinde orfaninin stres, anksiyete, öğrenme-hafıza ve bağımlılıkla ilgisi araştırılmıştır. Bu yazının amacı, sarı kantaron bitkisinin farmakolojik ve klinik olarak elde edilen verilerini derlemek, orfanin hakkında bilgi vermek ve depresyonu önlemede kantaron ve orfanin arasındaki olası ilişkiyi değerlendirmektir.

Anahtar Kelimeler

Antidepresan etki, hypericum perforatum, Orfanin FQ/nosiseptin, St. John bitkisi

Kaynakça

• Stjepanović-Veselčić, L. Hypericaceae. In Flora of Serbia, 1st ed.(Ed M Josifović):104-25. SANU, Belgrade, Serbia. 1972.
• Nathan PJ. Hypericum perforatum (St John's Wort): a non-selective reuptake inhibitor? a review of the recent advances in its pharmacology. J Psychopharmacol. 2001;15: 47–54.
• Klemow KM, Bartlow A, Crawford J, Kocher N, Shah J, Ritsick M. Medical attributes of St. John’s Wort (Hypericum perforatum). In Herbal Medicine: Biomolecular and Clinical Aspects, 2nd edition (Eds: IFF Benzie, S Wachtel-Galor):Chp 11 . Boca Raton, FL, CRC Press, 2011.
• BSBI List 2007 (xls). Botanical Society of Britain and Ireland. Archived from the original on 2015- 02-25. archive. bsbi.org.uk/ScottishNsl2007.pdf (accessed March 2015)
• The National Center for Complementary and Alternative Medicine (NCCAM). Development of a Comprehensive, National Research Strategy for Complementary and Alternative Medicine, 2000. https://nccih.nih.gov/about/offices/od/directortestimony/071100.htm. on 16 (accessed March 2015)
• National Center for Complementary and Alternative Medicine (NCCAM) : National Institutes of Healt (NIH). Herbs at a glance: St. John's wort. https://nccih.nih.gov/health/stjohnswort/ataglan (accessed March 2015)
• National Center for Complementary and Alternative Medicine (NCCAM): National Institutes of Health. What the science says about St. John's wort for depression. https://nccih.nih.gov/health/stjohnswort/sjw-and-depression.htm(accessed March 2015)
• WHO. Monographs on Selected Medicinal Plants, vol 2. Herba Hyperici. World Health Organization, Geneva, 2004.
• Sweety M. Pharmacognosy of St. John's Wort. Pharmaxchange.info .(accessed March 2015)
• Hammer KDP, Hillwig ML, Solco AKS, Dixon PM. Inhibition of prostaglandin E2 production by anti-inflammatory Hypericum perforatum extracts and constituents in RAW264.7 mouse macrophage cells. J Agr Food Chem. 2007;55:7323–31.
• Savikin K, Dobri´c S, Tadi´c V, Zduni´c G. Antiinflammatory activity of ethanol extracts of Hypericum perforatum L., H. barbatum Jacq., H. hirsutum L., H. richeri Vill. and H. androsaemum L. in rats. Phytother Res. 2007;21:176–80.
• Rao SG, Udupa SL, Rao PGM, Rao G, Kulkurni DR. Calendula and Hypericum: two homeopathic drugs promoting wound healing in rats. Fitoterapia.1991;6:508–10.
• Öztürk N, Korkmaz S, Öztürk Y. Wound-healing activityof St. John’s Wort (Hypericum perforatum L.) on chicken embryonic fibroblasts. J Ethnopharmacol. 2007;11:33–9.
• Zdunić G, Godevac D, Milenković M, Vucićević D, Savikin K, Menković N et al. Evaluation of Hypericum perforatum oil extracts for an antiinflammatory and gastroprotective activity in rats. Phytother Res. 2009;23:1559–64.
• Ebadi M. Pharmacodynamic Basis of Herbal Medicine, 2nd edition. Florida, Taylor & Francis, 2007.
• Butterweck V. Mechanism of action of St John's wort in depression: what is known? CNS Drugs. 2003; 17:539-62.
• Linde K, Berner MM, Kriston L. St John's wort for major depression. Cochrane Database Syst Rev. 2008; 4:CD000448.
• Linde K, Ramirez G, Mulrow CD, Pauls A, Wolfgang Weidenhammer W, Melchart D. St John's wort for depression-an overview and meta-analysis of randomised clinical trials. BMJ. 1996;313:253-8.
• Pharmacology Weekly. What is the mechanism of action of Hypericum perforatum in the treatment of depression.2009, www.Pharmacologyweekly(accessed March 2015)
• Neary JT, Bu Y. Hypericum LI 160 inhibits uptake of serotonin and norepinephrine in astrocytes. Brain Res. 1999;816:358-63.
• Chatterjee SS, Bhattacharya SK, Wonnemann M, Singer A, Müller WE. Hyperforin as a possible antidepressant component of hypericum extracts. Life Sci. 1998;63:499-510.
• Baureithel KH, Büter KB, Engesser A,Burkard W,Schaffner W. Inhibition of benzodiazepine binding in vitro by amentoflavone, a constituent of various species of hypericum. Pharm Acta Helv. 1997;72:153-7.
• Muller WE, Rolli M, Schäfer C, Hafner U. Effects of hypericum extract (LI 160) in biochemical models of antidepressant activity. Pharmacopsychiatry 1997;3 :102-7.
• Thiede HM, Walper A. Inhibition of MAO and COMT by hypericum extracts and hypericin. J Geriatr Psychiatry Neurol. 1994;7:54-6.
• Meunier JC, Mollereau C,Toll L, Suaudeau C, Moisand C, Alvinerie P et al. Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor. Nature.1995;377:532–5.
• Reinscheid RK, Ardati A, Mon-sma, FJJr,Civelli O. Structure-activityrelation- ship studies on the novel neu ropeptide orphanin FQ. J Biol Chem.1996;271:14163–8.
• Bunzow JR, Saez C, Mortrud M, Bouvier C, Williams JT, Low M et al. Molecular cloning and tissue distribution of a putative member of the rat opioid receptor gene family that is not a μ, δ or κ opioid receptor type. FEBS Letter. 1994;347:284–8.
• Mallimo EM, Kusnecov AW. The role of orphaninFQ/nociceptin in neuroplasticity: relationship to stress, anxiety and neuroinflammation. Front Cell Neurosci. 2013;8:173.
• Mollereau C,Parmentier M, Mailleux P, Butour JL, Moisand C, Chalon Pet al. ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization. FEBS Lett. 1994;341:33–8.
• Hawes BE, Graziano MP, Lambert DG. Cellular actions of nociceptin: transduction mechanisms. Peptides. 2000;21:961–7.
• Altier C, Zamponi GW. Signaling complexes of voltage-gated calcium channels and G protein- coupled receptors. J Recept Signal Transduct Res. 2008;28:71-81.
• Schlicker E, Morari M. Nociceptin/orphaninFQ and neurotransmitter release in the central nervous system. Peptides.2000;21:1023– 9.
• Okuda-Ashitaka E, Minami T, Tachibana S,Yoshihara Y, Nishiuchi Y, Kimura T et al. Nocistatin, a peptide that blocks nociceptin action in pain transmission. Nature.1998;392:286-9.
• Rossi GC, Perlmutter M, Leventhal, L, Talatti A, Pasternak GW. OrphaninFQ/nociceptin analgesia in the rat. Brain Res. 1998;792:327–30.
• Nothacker HP, Reinscheid RK, Mansour A, Henningsen RA, Ardati A, Monsma FJ Jr etal. Primary structure and tissue distribution of the orphanin FQ precursor. Proc Natl Acad Sci. 1996;93:8677– 82.
• Pampusch MS, Serie JR, Osinski MA, Seybold VS, Murtaugh MP, Brown DR. Expression of nociceptin/OFQ receptor and prepro-nociceptin/OFQ in lymphoid tissues. Peptides. 2000;21:1865–70.
• Noda Y, Mamiya T, Manabe T, Nishi M, Takeshima H ,Nabeshima T. Role of nociceptin systems in learning and memory. Peptides. 2000;21:1063–9.
• Zaveri NT.The nociceptin/orphanin FQ receptor (NOP) as a target for drug abuse medications. Curr Top Med Chem. 2011;11:1151–6.
• Devine DP, Watson SJ, Akil H. Nociceptin/orphanin FQ regulates neuroendocrine function of the limbic-hypothalamic- pituitary-adrenal axis. Neuroscience. 2001;102:541–53.
• Nicholson JR, Akil H, Watson SJ. Orphanin FQ-induced hyperphagia is mediated by corticosterone and central glucocorticoid receptors. Neuroscience. 2002;115:637–43.
• Vitale G, Arletti R, Ruggieri V, Cifani C, Massi M. Anxiolytic- like effects of nociceptin/orphanin FQ in the elevated plus maze and in the conditioned defensive burying test in rats. Peptides. 2006;27:2193–200.
• Köster A, Montkowski A, Schulz S, Stübe EM, Knaudt K, Jenck F et al. Targeted disruption of the orphanin FQynociceptin gene increases stress susceptibility and impairs stress adaptation in mice. Proc Natl Acad Sci. 1999;96:10444–9.
• Liu Z, Wang Y, Zhang J, Ding J, Guo L, Cui D et al. Orphanin FQ: an endogenous antagonist of rat brain dopamine transporter. NeuroReport. 2001;12:699–702.
• Calo' G, Guerrini R, Rizzi A, Salvadori S, Regoli D. Pharmacology of nociceptin and its receptor: a novel therapeutic target. Br J Pharmacol. 2000;129:1261–83.
• Correspondence Address / Yazışma Adresi